ERS Genomics Limited ('ERS'), the CRISPR licensing company, and Dyadic Applied BioSolutions ('Dyadic'), a global ...

Access to ERS Genomics’ foundational CRISPR/Cas9 patent portfolio expands our genetic engineering toolkit and strengthens our ability to speed up and optimize strain development across Dyadic’s ...

ERS Genomics Limited ('ERS'), the CRISPR licensing company, and Dyadic Applied BioSolutions, a global biotechnology company producing precision-engineered ...

One-time treatment of nex-z led to consistently rapid, deep and durable reduction in serum TTR through three years of follow-upConsistent trend ...

Media are invited to join the Honourable Buckley Belanger Secretary of State (Rural Development) on behalf of the Honourable Gregor Robertson, Minister of Housing and Infrastructure and Minister ...

Propy, the AI-powered title and escrow platform modernizing U.S. real estate closings, today announced its first acquisition under its $100M AI-led national expansion plan: a premier title company in ...

The company scans entire proteins with CRISPR to find functional vulnerabilities, then hunts for molecules that exploit them ...

Advances in genome editing have transformed the development of animal models used to understand human diseases. While transgenic mouse models have broadly ...

Successful fertilization in flowering plants depends on healthy pollen development and structural integrity of the pollen wall.

Enhancers play a crucial role in directing gene expression programs essential for cellular differentiation and development. Recent advancements in 3D genome ...

Investigators who designed a base-editing treatment are planning an "umbrella of umbrellas" trial, while others are developing roadmaps to guide personalized treatments.

In a 15-patient, Phase 1 one, first-in-human trial, a one-time, CRISPR-Cas9 gene-editing therapy safely reduced LDL ...